{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/prescribing-information/escitalopram-paroxetine-sertraline/","result":{"pageContext":{"chapter":{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline","depth":2,"htmlHeader":"<!-- begin field 5d44a94b-519c-4d3b-b8a9-6b9a5b935dfe --><h2>Escitalopram, paroxetine, and sertraline</h2><!-- end field 5d44a94b-519c-4d3b-b8a9-6b9a5b935dfe -->","summary":"","htmlStringContent":"<!-- begin item 6801024f-3459-4ab3-9066-787eed4539c0 --><!-- end item 6801024f-3459-4ab3-9066-787eed4539c0 -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"be6c59d0-20b8-5bfd-bc2b-efd0f4dc2676","slug":"general-information","fullItemName":"General information","depth":3,"htmlHeader":"<!-- begin field 1193a8f5-e0aa-44d1-a056-a814016f6b1a --><h3>General information</h3><!-- end field 1193a8f5-e0aa-44d1-a056-a814016f6b1a -->","summary":"","htmlStringContent":"<!-- begin item 3b46fc33-734b-4da6-ae91-a814016f5c81 --><!-- begin field e3efd96e-fcf4-4e41-91da-a814016f6b1a --><ul><li><strong>The SSRIs most commonly prescribed in the UK for the treatment of generalized anxiety disorder (GAD) are:</strong><ul><li>Sertraline (Lustral).</li><li>Paroxetine (Seroxat).</li><li>Escitalopram (Cipralex).</li></ul></li><li>There is no evidence that any one is more effective than the others in the treatment of GAD.</li><li>Escitalopram and paroxetine are licensed in the UK for the treatment of generalized anxiety disorder, whilst the others are not.</li><li>Sertraline is often used first-line as it is the most cost-effective, but as it is not licensed for the treatment of GAD, informed consent should be obtained and documented.</li><li>Other known clinical advantages of sertraline include its minimal drug interactions (making it preferable to paroxetine), a lack of associated electrocardiographic changes (compared with escitalopram), and its lower risk of symptoms on discontinuation (compared with paroxetine).</li><li>Choice of SSRI should also take into account the person's preference, and their prior experience of treatment with individual drugs (particularly adherence, effectiveness, side effects, and experience of withdrawal syndrome).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">NICE, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Hoge and Fricchione, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field e3efd96e-fcf4-4e41-91da-a814016f6b1a --><!-- end item 3b46fc33-734b-4da6-ae91-a814016f5c81 -->","subChapters":[]},{"id":"11a19ce2-9eed-5256-939a-6f1629eeb1a6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f70e6bed-d98b-4b2b-bdc4-a76000d1eb61 --><h3>Contraindications and cautions</h3><!-- end field f70e6bed-d98b-4b2b-bdc4-a76000d1eb61 -->","summary":"","htmlStringContent":"<!-- begin item 1fc0f237-5309-427a-a767-a76000d1eb59 --><!-- begin field e4282d7f-3c70-4fcb-b545-a76000d1eb61 --><ul><li><strong>Do not prescribe SSRIs</strong> <strong>to people:</strong><ul><li>In a manic phase of bipolar disorder.</li><li>Taking monoamine oxidase inhibitors (MAOIs), or who have recently discontinued a MAOI.</li><li>Taking pimozide.</li><li>With uncontrolled epilepsy or new onset seizures.</li></ul></li><li><strong>Do not prescribe escitalopram to people with:</strong><ul><li>Known QT interval prolongation, or taking medication known to prolong the QT interval.</li><li>Congenital long QT syndrome.</li></ul></li><li><strong>Do not prescribe paroxetine in combination with:</strong><ul><li>Thioridazine — this can elevate plasma levels of thioridazine, increasing the risk of QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death.</li><li>Pimozide.</li></ul></li><li><strong>Prescribe SSRIs with caution</strong> <strong>to people with:</strong><ul><li>Cardiac disease.</li><li>Epilepsy (discontinue if convulsions develop).</li><li>A history of bleeding disorders, especially gastrointestinal bleeding.<ul><li>Older people or people taking drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin) may also be at risk. Consider prescribing a gastroprotective drug in these circumstances.</li></ul></li><li>Diabetes mellitus.</li><li>History of mania.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Also prescribe with caution to those undergoing concurrent electroconvulsive therapy.</li></ul></li><li><strong>In addition, prescribe escitalopram with caution to people at a higher risk than average of developing Torsade de Pointes. This includes people with:</strong><ul><li>Congestive heart failure.</li><li>Recent myocardial infarction.</li><li>Bradyarrhythmias.</li><li>Concomitant illness or medication causing a predisposition to hypokalemia or hypomagnesaemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field e4282d7f-3c70-4fcb-b545-a76000d1eb61 --><!-- end item 1fc0f237-5309-427a-a767-a76000d1eb59 -->","subChapters":[]},{"id":"dfafb7f7-5353-5b52-af25-f69f98642fe9","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ddfec621-6612-4850-8ffd-a76000d1fd7b --><h3>What adverse effects are associated with SSRIs?</h3><!-- end field ddfec621-6612-4850-8ffd-a76000d1fd7b -->","summary":"","htmlStringContent":"<!-- begin item a7472ea4-742e-497e-8aef-a76000d1fe0b --><!-- begin field 40c8c5d4-0a0b-401c-a05b-a76000d1fd7b --><ul><li><strong>The most common adverse effects associated with use of an SSRI are:</strong><ul><li><strong>Gastrointestinal effects </strong>— these are dose-related and include nausea, vomiting, abdominal pain, dyspepsia, constipation, and diarrhoea.</li><li><strong>Central nervous system effects</strong> — including dizziness, agitation, anxiety, insomnia, headache, and tremor.</li><li><strong>Drowsiness </strong>— may impair performance of skilled tasks such as driving and operating machinery.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">DVLA, 2015</a>].</li></ul></li><li><strong>Sexual dysfunction </strong>— this is also a common symptom of generalized anxiety disorder.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li><strong>Increased risk of bleeding,</strong> especially in older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li><strong>Increased risk of fractures </strong>— the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that SSRIs are associated with a small increased risk of fractures; however, the mechanism leading to this is unclear and may be multifactorial. </li><li><strong>Hyponatraemia </strong>— risk factors for developing hyponatraemia include a history of hyponatraemia, extreme old age (greater than 80 years of age), female sex, low body weight, diuretics, diabetes mellitus, hypertension, reduced renal function, volume depletion, and chronic obstructive pulmonary disease.<ul><li>Monitor the person for signs and symptoms of hyponatraemia (such as dizziness, lethargy, nausea, confusion, cramps, and seizures).</li></ul></li><li><strong>Increased suicide risk</strong> — this is most likely in younger people (less than 30 years of age) when starting an SSRI.<ul><li>Monitor people carefully during the first few weeks of SSRI treatment; in particular, be alert for signs of suicidal ideation, akathisia, and increased anxiety and agitation. For more information on monitoring suicide risk, see the section <a class=\"topic-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/management/management/#risk-of-suicide\">How should I assess a person&#39;s risk of suicide?</a>.</li></ul></li><li><strong>Discontinuation symptoms</strong> (such as dizziness, sensory disturbances [including paraesthesia], sleep disturbances [including insomnia and intense dreams], agitation or anxiety, nausea and/or vomiting, tremor, and headache).<ul><li>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. </li><li>Generally these symptoms are mild to moderate; however in some people they may be severe.</li><li>They usually occur within the first few days of discontinuing treatment.</li><li>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 – 3 months or more).</li><li>It is therefore advised that an SSRI should be gradually tapered over a period of several weeks or months, according to the person's needs.</li><li>Paroxetine is associated with a higher incidence of discontinuation symptoms compared with other selective serotonin reuptake inhibitors.</li></ul></li><li><strong>For escitalopram,</strong> <strong>QT prolongation and/or ventricular arrhythmias</strong>; especially in women, people with hypokalaemia, or people with pre-existing QT prolongation or other cardiac disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field 40c8c5d4-0a0b-401c-a05b-a76000d1fd7b --><!-- end item a7472ea4-742e-497e-8aef-a76000d1fe0b -->","subChapters":[]},{"id":"bb3fae96-55d4-5755-a64d-91456f13d778","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 52f8fbdd-4a2a-4551-9552-a76000d2125d --><h3>What are the key drug interactions with SSRIs?</h3><!-- end field 52f8fbdd-4a2a-4551-9552-a76000d2125d -->","summary":"","htmlStringContent":"<!-- begin item d1324b30-d3ef-4800-9ca6-a76000d21291 --><!-- begin field e47e9718-5bb5-42ff-8e05-a76000d2125d --><p><strong>Key drug interactions with SSRIs as a class include:</strong></p><ul><li>5HT<sub>3</sub>-receptor antagonists, dapoxetine, duloxetine, fentanyl, naratriptan, St John's Wort — possible increased serotonergic effects.<ul><li>The manufacturer of dapoxetine advises SSRIs should not be started until 1 week after stopping dapoxetine, and to avoid dapoxetine for 2 weeks after stopping SSRIs.</li></ul></li><li>Antiepileptics —SSRIs antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered).</li><li>Aspirin, dabigatran, and NSAIDs — increased risk of bleeding.</li><li>Coumarins — SSRIs possibly enhance anticoagulant effect of coumarins.<ul><li>Consider frequent monitoring of the INR. Any change in the person's clinical condition, particularly liver disease, intercurrent illness, or drug administration, necessitates more frequent monitoring of the INR. </li></ul></li><li>Cyproheptadine — antidepressant effect of SSRIs possibly antagonised by cyproheptadine.</li><li>Lithium — increased risk of CNS effects when SSRIs given with lithium (lithium toxicity reported).<ul><li>Advise the person be alert for symptoms such as decreased appetite, diarrhoea, vomiting, ataxia, nystagmus, dysarthria, confusion, and seizures. Consider frequent monitoring of lithium levels.</li></ul></li><li>MAOIs — CNS effects of SSRIs increased by MAOIs (risk of serious toxicity).</li><li>Methylphenidate — metabolism of SSRIs possibly inhibited.</li><li>Pimozide — SSRIs possibly increase plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use).</li><li>Rasagiline, Tramadol — increased risk of CNS toxicity.</li><li>Ritonavir — plasma concentration of SSRIs possibly increased.</li><li>Serotonergic medicines — concurrent use of sertraline with other serotonergic medicines increases the risk of serotonin syndrome or neuroleptic malignant syndrome.</li><li>Tricyclic antidepressants — SSRIs increase plasma concentration of some tricyclics</li><li>Vortioxetine — possible increased risk of convulsions.</li></ul><p><strong>Key drug interactions with specific SSRIs include:</strong></p><ul><li>Escitalopram — do not prescribe concurrently with drugs that prolong the QT interval (including some antiarrhythmics (such as amiodarone), antipsychotics (such as haloperidol), antihistamines (such as mizolastine), and antiretrovirals (such as ritonavir, saquinavir, and lopinavir).</li><li>Paroxetine:<ul><li>Avoid concurrent use with tamoxifen. Paroxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy.</li><li>Paroxetine may increase the plasma concentrations of aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine.</li><li>Paroxetine may inhibit the metabolism of atomoxetine, perphenazine, and propafenone.</li><li>Plasma concentration of paroxetine may be altered by asenapine, darunavir, fosphenytoin, phenobarbital, phenytoin, primidone, ritonavir, and terbinafine.</li><li>There is an increased risk of CNS toxicity when paroxetine is given with sumatriptan.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2021</a>]</p><!-- end field e47e9718-5bb5-42ff-8e05-a76000d2125d --><!-- end item d1324b30-d3ef-4800-9ca6-a76000d21291 -->","subChapters":[]},{"id":"8d06d079-b796-58b1-8d2f-26bcf49e300b","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field ed9c9d3c-909c-4fa5-9e7e-a76000d240c7 --><h3>What dose of escitalopram, paroxetine, or sertraline should I use and how should I titrate the dose?</h3><!-- end field ed9c9d3c-909c-4fa5-9e7e-a76000d240c7 -->","summary":"","htmlStringContent":"<!-- begin item d2f007e1-b126-4a8d-9643-a76000d240fc --><!-- begin field 024db89a-3fe6-4429-afd2-a76000d240c7 --><ul><li><strong>For escitalopram:</strong> prescribe a starting dose of 10 mg a day. Dose may be increased to a maximum of 20 mg a day (except in elderly people and those with reduced hepatic function).</li><li><strong>For paroxetine: </strong>prescribe a starting dose of 20 mg a day. The maximum licensed dose for the treatment of generalized anxiety disorder (GAD) is 50 mg/day.</li><li><strong>For sertraline: </strong>prescribe a starting dose of 25 mg a day. Dose may gradually be increased to a maximum of 200 mg a day.<ul><li>Be aware that sertraline is not licensed for use in GAD. The recommended doses are licensed doses for social anxiety disorder and panic disorder.</li></ul></li><li><strong>If changing between anxiolytic medications:</strong><ul><li>When switching from one SSRI to another, cross tapering is not necessary, as the new drug will generally ameliorate withdrawal symptoms from the old one.</li><li>When switching from an SSRI to an SNRI, cautious cross tapering using a low dose SNRI is generally recommended. However, an abrupt switch to duloxetine 60 mg/day is possible.</li><li>When switching from an SNRI to an SSRI, cross taper cautiously, starting with low dose SSRI.</li><li>For information on switching to and from other groups of antidepressants, see the section on switching antidepressants in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Taylor, 2015</a>]</p><!-- end field 024db89a-3fe6-4429-afd2-a76000d240c7 --><!-- end item d2f007e1-b126-4a8d-9643-a76000d240fc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}